belfasttelegraph Wednesday, 26 November, 2014

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Search news from around the web

  1. NEW YORK (TheStreet) -- As the S&P 500 continues to make new record highs, investors may be found scratching their head when looking for a good value. According to Derek Bruton, CEO of Lucia Capital, there are still several good bargains in the stock market. In an interview with TheStreet TV's Gregg Greenberg, his first pick was Dow Chemical . Must Read: 7 Stocks Warren Buffett Is Selling in 2014 Gilead Sciences GILD and NXP Semiconductor NXPI data by YCharts Investors should like the company because it's leveraging natural gas production and shale oil production, Bruton reasoned. "It's a cash-rich" company, he added, and it continues to return that cash to shareholders. Dow recently boosted its dividend by 14%, while also adding $5 billion to its share repurchase plan, bringing the total program to $9.5 billion. The company is also divesting from some of its low-margin businesses, Bruton said. Turning to NXP Semiconductors , Bruton says he likes this company because it's one of the most direct plays on Apple's iPhone 6. NXP Semiconductor makes the chips used for Apple Pay, he said, a platform that will "revolutionize the consumer payment industry." The company also has products in drivers licenses, passports and the Wi-Fi used in automobiles. NXP Semi is way ahead of its competition, he added. Finally, Bruton turned to his last pick, Gilead Sciences . The company has recently faced controversy over the cost of its hepatitis C treatment, which costs $84,000 in the U.S. Gilead is an "innovative biotech company," he said, that has a great pipeline with treatments outside of hep C, including cardiovascular disease and HIV. At just 10 times next year's earnings, the stock is "extremely inexpensive" and investors should use the recent selloff as a buying opportunity, he concluded. Must Read: Why Apple Pay and Other Mobile Payments Will Explode in the Next Five Years -- Written by Bret Kenwell Follow @BretKenwell // 0;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document ... FULL ARTICLE AT The Street

  2. Gilead Sciences (GILD) in the Medicine-Biomedicine space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. FULL ARTICLE AT Zacks Investment Research

  1. Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the ... FULL ARTICLE AT The Street

  2. Source Celgene Corporation. Gilead Sciences fast growing hepatitis C drugs Sovaldi and Harvoni may have made it one of the stock market's best performers this past year, but it ... FULL ARTICLE AT NASDAQ

  3. UBS strategist Matthew Roden and team note that it was another good week Gilead Sciences’ (GILD) hepatitis-C treatments: AP Scripts for Gilead’s Harvoni during the week ending November 14 ... FULL ARTICLE AT Barron's

  1. Gilead Sciences, Inc. has entered into an agreement to purchase neglected tropical disease priority review voucher from Canada based Knight Therapeutics Inc. FULL ARTICLE AT Zacks Investment Research

  2. The folks at Wells Fargo are bullish on Gilead Sciences (GILD) and its hepatitis-C franchise, but decided to work out the worst case scenario, just in case. Analyst Brian Abrahams ... FULL ARTICLE AT Barron's

  3. MONTREAL, QUEBEC--(Marketwired - Nov. 19, 2014) - Knight Therapeutics Inc., (TSX:GUD) through one of its wholly owned subsidiaries ("Knight"), today announced the sale of its Neglected Tropical Disease Priority Review ... FULL ARTICLE AT Marketwire

  4. Ad campaign attacks use of Gilead's Truvada as way to prevent HIV

    An AIDS patient advocacy group and pharmacy operator is taking on the Centers for Disease Control — and by extension Gilead Sciences Inc. — in a national ad campaign centering on a ... FULL ARTICLE AT San Francisco Business Times

About this topic

Wikipedia

Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The... Full Article At Wikipedia.org

Timeline of coverage

  1. Click to see all coverage from 2014-10-12
    2014-10-12
  2. Click to see all coverage from 2014-10-13
    2014-10-13
  3. Click to see all coverage from 2014-10-14
    2014-10-14
  4. Click to see all coverage from 2014-10-15
    2014-10-15
  5. Click to see all coverage from 2014-10-16
    2014-10-16
  6. Click to see all coverage from 2014-10-17
    2014-10-17
  7. Click to see all coverage from 2014-10-18
    2014-10-18
  8. Click to see all coverage from 2014-10-19
    2014-10-19
  9. Click to see all coverage from 2014-10-20
    2014-10-20
  10. Click to see all coverage from 2014-10-21
    2014-10-21
  11. Click to see all coverage from 2014-10-22
    2014-10-22
  12. Click to see all coverage from 2014-10-23
    2014-10-23
  13. Click to see all coverage from 2014-10-24
    2014-10-24
  14. Click to see all coverage from 2014-10-25
    2014-10-25
  15. Click to see all coverage from 2014-10-26
    2014-10-26
  16. Click to see all coverage from 2014-10-27
    2014-10-27
  17. Click to see all coverage from 2014-10-28
    2014-10-28
  18. Click to see all coverage from 2014-10-29
    2014-10-29
  19. Click to see all coverage from 2014-10-30
    2014-10-30
  20. Click to see all coverage from 2014-10-31
    2014-10-31
  21. Click to see all coverage from 2014-11-01
    2014-11-01
  22. Click to see all coverage from 2014-11-02
    2014-11-02
  23. Click to see all coverage from 2014-11-03
    2014-11-03
  24. Click to see all coverage from 2014-11-04
    2014-11-04
  25. Click to see all coverage from 2014-11-05
    2014-11-05
  26. Click to see all coverage from 2014-11-06
    2014-11-06
  27. Click to see all coverage from 2014-11-07
    2014-11-07
  28. Click to see all coverage from 2014-11-08
    2014-11-08
  29. Click to see all coverage from 2014-11-09
    2014-11-09
  30. Click to see all coverage from 2014-11-10
    2014-11-10
  31. Click to see all coverage from 2014-11-11
    2014-11-11
  32. Click to see all coverage from 2014-11-12
    2014-11-12
  33. Click to see all coverage from 2014-11-13
    2014-11-13
  34. Click to see all coverage from 2014-11-14
    2014-11-14
  35. Click to see all coverage from 2014-11-15
    2014-11-15
  36. Click to see all coverage from 2014-11-16
    2014-11-16
  37. Click to see all coverage from 2014-11-17
    2014-11-17
  38. Click to see all coverage from 2014-11-18
    2014-11-18
  39. Click to see all coverage from 2014-11-19
    2014-11-19
  40. Click to see all coverage from 2014-11-20
    2014-11-20
  41. Click to see all coverage from 2014-11-21
    2014-11-21
  42. Click to see all coverage from 2014-11-22
    2014-11-22
  43. Click to see all coverage from 2014-11-23
    2014-11-23
  44. Click to see all coverage from 2014-11-24
    2014-11-24
  45. Click to see all coverage from 2014-11-25
    2014-11-25
  46. Click to see all coverage from 2014-11-26
    2014-11-26

Login

Login to make editorial changes to the current page.

Login Cancel

Close